Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (3755)	10/9/1999 5:10:00 PM
From: Vector1	Read Replies (1) \| Respond to of 10280

RKW, No question not having a MDI is a disadvantage. However, those most likely to benefit from Xopenex are older people with severe lung disfunction who are regularly breathing Albuterol from a nebulizer. IF the study confirms Xopenex's advantage in lack of impairment of long term lung function then they should dominate that market. One of the reasons the market seems small is becuase Albuterol is a generic. The size of the market will grow by increased pricing that Xopenex will be able to command. V1